Rnal.pone.0055869.tFADS Gene, Desaturase Activity and CADTable 6. Effects of rs174460 SNP on lipids and plasma fatty acid levels.CharacteristicsControls TT(n = 323) CC+CT(n = 187) 4.17(3.58, 4.82)g 1.05(0.80, 1.43) 1.17(0.96, 1.39) 2.4460.g g gCAD patients TT(n = 284) 4.03(3.31, 4.67)* 1.23(0.93, 1.71)*, 1.11(0.92, 1.32)* 2.39(1.73, 2.82)* 5.92(5.26, 6.42)* 23.2163., ,CC+CT(n = 221) 4.44(3.98, 5.19) ,1 1.47(1.04, 1.77) ,1,# 1.17(1.08, 1.40) ,# 2.58(2.32, 3.26) ,1 5.47(4.99, 6.22) ,1,# 23.1361.871 0.96(0.71, 1.26)1,# 9.1961.05 16.4462.70#,1 33.5764.041,# 0.29(0.13, 0.45)#, ,TC(mmol/l)1 TG(mmol/l)1 HDL-C (mmol/l) LDL-C(mmol/l) FPG (mmol/l)1 2,3 1 1 1,4.38(3.91, 4.77) 0.98(0.77, 1.34) 1.34(1.14, 1.56) 2.6960.46 4.91(4.60, 5.22) 22.5863.87 0.61(0.44, 0.91) 9.0962.03 14.7663.32 36.83(32.86, 40.79)1 15.19(4.63, 5.93) 21.7664.02 0.71(0.49, 0.93) 8.7262.23 14.6463.Palmitic acid, C16:Palmitoleic acid, C16:1 Stearic acid, C18:2,0.96(0.70, 1.25)* 9.2661.34 16.3162.72*, 33.5164.80 0.31(0.16, 0.50)* 0.64(0.46, 0.84)* 1.52(1.21, 1.84)* 8.1062.Oleic acid, C18:1n-92 Linoleic acid, C18:2n-62,3 c-linolenic acid, C18:3n-35.67(30.41, 39.11)g 0.21(0.01, 0.60) 0.43(0.27, 0.65) 1.36(1.00, 1.81) 7.7462.60 0.10(0.00, 0.30) 2.6261.09 6.31(3.97, 8.65) 0.2460.09 0.03(0.02, 0.04)g 1.7560.43g0.14 (0.00, 0.39) 0.45(0.29, 0.70) 1.26(0.95, 1.71) 7.8962.46 0.09(0.00, 0.29) 2.8461.04 6.65(4.49, 8.56) 0.2260.08 0.03(0. 02, 0.04) 1.6560.a -linolenic acid, C18:3n-0.66(0.41, 0.86)1,# 1.54(1.20, 1.96)1,# 7.8961.91 0.30(0.00, 0.52)1,# 2.5260.69# 5.20(3.80, 6.79)1,# 0.2560.08# 0.04(0.03, 0.05)1,# 1.8160.41#Dihomo-c-linolenic acid, C20:3n-6 Arachidonic acid, C20:4n-Eicosapentaenoic acid, C20:5n-31 Docosahexaenoic acid, C22:6n-32 C20:4n-6/C20:3n-6 (D5D) C16:1/C16:0 (D9D-16)1 C18:1n-9/C18:0 (D9D-18)0.27(0.00, 0.46)*, 2.6360.78* 5.12(3.82, 7.65)* 0.2560.10* 0.04(0.03, 0.05)*, 1.7960.41*C20:4n-6/C18:2n-6 (D6D)1: Median (25 Percentiles, 75 Percentiles). 2: Mean6SD. 3: The data were logarithmically transformed. g: Control-TT vs Control-CC+CT, *: Control-TT vs CAD-TT, #:Control-TT vs CAD-CC+CT. : Control-CC+CT vs CAD-TT, 1:Control-CC+CT vs CAD-CC+CT, : CAD-TT vs CAD-CC+CT. doi:10.1371/journal.pone.0055869.trespectively) [24]. SR-3029 manufacturer Malerba G [25] also showed a significant correlation between FADS3 polymorphism (rs1000778) and PUFAs. In the present study, carriers of rs174460 C allele had a higher level of DGLA. In an earlier report, Kim OY [3] 18325633 showed a similar result in individuals with more features of metabolic syndrome and arterial stiffness. They proposed that impaired fatty acids metabolism may cause the accumulation of DGLA, possibly as a consequence of long-term metabolic disorders. This theory was based on reports by Warensjo et al. [6] and others [3]: LA and a ?linolenic acid (ALA, C18:3n-3) in plasma lipid esters reflect the dietary fatty acid intake 6? weeks before measurement. However, C16:1 and DGLA do not reflect the dietary intake of those fatty acids but are synthesized endogenously by a series of desaturation step. Several studies, including genome-wide MedChemExpress HIV-RT inhibitor 1 association studies, showed associations between SNPs in the FADS gene cluster and lipid levels, such as HDL-C, LDL-C and TG [26,27]. Although our study also showed significant difference in lipid levels with SNPs between the two groups, the results were not fully consistent with previous reports, such as TC and LDL-C were decreased in CAD patients. The main reason was the effect of drugs or treatments. Many patients.Rnal.pone.0055869.tFADS Gene, Desaturase Activity and CADTable 6. Effects of rs174460 SNP on lipids and plasma fatty acid levels.CharacteristicsControls TT(n = 323) CC+CT(n = 187) 4.17(3.58, 4.82)g 1.05(0.80, 1.43) 1.17(0.96, 1.39) 2.4460.g g gCAD patients TT(n = 284) 4.03(3.31, 4.67)* 1.23(0.93, 1.71)*, 1.11(0.92, 1.32)* 2.39(1.73, 2.82)* 5.92(5.26, 6.42)* 23.2163., ,CC+CT(n = 221) 4.44(3.98, 5.19) ,1 1.47(1.04, 1.77) ,1,# 1.17(1.08, 1.40) ,# 2.58(2.32, 3.26) ,1 5.47(4.99, 6.22) ,1,# 23.1361.871 0.96(0.71, 1.26)1,# 9.1961.05 16.4462.70#,1 33.5764.041,# 0.29(0.13, 0.45)#, ,TC(mmol/l)1 TG(mmol/l)1 HDL-C (mmol/l) LDL-C(mmol/l) FPG (mmol/l)1 2,3 1 1 1,4.38(3.91, 4.77) 0.98(0.77, 1.34) 1.34(1.14, 1.56) 2.6960.46 4.91(4.60, 5.22) 22.5863.87 0.61(0.44, 0.91) 9.0962.03 14.7663.32 36.83(32.86, 40.79)1 15.19(4.63, 5.93) 21.7664.02 0.71(0.49, 0.93) 8.7262.23 14.6463.Palmitic acid, C16:Palmitoleic acid, C16:1 Stearic acid, C18:2,0.96(0.70, 1.25)* 9.2661.34 16.3162.72*, 33.5164.80 0.31(0.16, 0.50)* 0.64(0.46, 0.84)* 1.52(1.21, 1.84)* 8.1062.Oleic acid, C18:1n-92 Linoleic acid, C18:2n-62,3 c-linolenic acid, C18:3n-35.67(30.41, 39.11)g 0.21(0.01, 0.60) 0.43(0.27, 0.65) 1.36(1.00, 1.81) 7.7462.60 0.10(0.00, 0.30) 2.6261.09 6.31(3.97, 8.65) 0.2460.09 0.03(0.02, 0.04)g 1.7560.43g0.14 (0.00, 0.39) 0.45(0.29, 0.70) 1.26(0.95, 1.71) 7.8962.46 0.09(0.00, 0.29) 2.8461.04 6.65(4.49, 8.56) 0.2260.08 0.03(0. 02, 0.04) 1.6560.a -linolenic acid, C18:3n-0.66(0.41, 0.86)1,# 1.54(1.20, 1.96)1,# 7.8961.91 0.30(0.00, 0.52)1,# 2.5260.69# 5.20(3.80, 6.79)1,# 0.2560.08# 0.04(0.03, 0.05)1,# 1.8160.41#Dihomo-c-linolenic acid, C20:3n-6 Arachidonic acid, C20:4n-Eicosapentaenoic acid, C20:5n-31 Docosahexaenoic acid, C22:6n-32 C20:4n-6/C20:3n-6 (D5D) C16:1/C16:0 (D9D-16)1 C18:1n-9/C18:0 (D9D-18)0.27(0.00, 0.46)*, 2.6360.78* 5.12(3.82, 7.65)* 0.2560.10* 0.04(0.03, 0.05)*, 1.7960.41*C20:4n-6/C18:2n-6 (D6D)1: Median (25 Percentiles, 75 Percentiles). 2: Mean6SD. 3: The data were logarithmically transformed. g: Control-TT vs Control-CC+CT, *: Control-TT vs CAD-TT, #:Control-TT vs CAD-CC+CT. : Control-CC+CT vs CAD-TT, 1:Control-CC+CT vs CAD-CC+CT, : CAD-TT vs CAD-CC+CT. doi:10.1371/journal.pone.0055869.trespectively) [24]. Malerba G [25] also showed a significant correlation between FADS3 polymorphism (rs1000778) and PUFAs. In the present study, carriers of rs174460 C allele had a higher level of DGLA. In an earlier report, Kim OY [3] 18325633 showed a similar result in individuals with more features of metabolic syndrome and arterial stiffness. They proposed that impaired fatty acids metabolism may cause the accumulation of DGLA, possibly as a consequence of long-term metabolic disorders. This theory was based on reports by Warensjo et al. [6] and others [3]: LA and a ?linolenic acid (ALA, C18:3n-3) in plasma lipid esters reflect the dietary fatty acid intake 6? weeks before measurement. However, C16:1 and DGLA do not reflect the dietary intake of those fatty acids but are synthesized endogenously by a series of desaturation step. Several studies, including genome-wide association studies, showed associations between SNPs in the FADS gene cluster and lipid levels, such as HDL-C, LDL-C and TG [26,27]. Although our study also showed significant difference in lipid levels with SNPs between the two groups, the results were not fully consistent with previous reports, such as TC and LDL-C were decreased in CAD patients. The main reason was the effect of drugs or treatments. Many patients.
